As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth

US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials

 
• By Dave Wallace
Waves Beach Horizon Sunset
As Amgen’s current biosimilars portfolio recedes, bigger opportunities are on the horizon in the next wave • Source: Shutterstock

More from Biosimilars

More from Products